PG combined with current chemotherapy agents was studied in breast cancer and found that PG could facilitate paclitaxel sensitivity in triple-negative human breast carcinoma cells via down-regulating survivin expression, an anti-apoptotic protein that acts as a caspase inhibitor [67,68]. Here, BIRC5 is linked to breast carcinoma.